PARP1 and cancer: Studies in the past have shown that inhibition of PARP can sensitize cancer cells to DNA damaging cytotoxic agents irrespective of HR status [17, 18], however, clinical use of PARPis in combination with DNA damaging chemotherapy is limited due to normal tissue toxicity [16].